Downregulation of the Proinflammatory Cytokine Response to Endotoxin by Pretreatment With the Nontoxic Lipid A Analog SDZ MRL 953 in Cancer Patients by.

Slides:



Advertisements
Similar presentations
Quantitative modeling of chronic myeloid leukemia: insights from radiobiology by Tomas Radivoyevitch, Lynn Hlatky, Julian Landaw, and Rainer K. Sachs Blood.
Advertisements

Alternative activation of macrophages by IL-4 impairs phagocytosis of pathogens but potentiates microbial- induced signalling and cytokine secretion by.
Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.
How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.
Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.
Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.
Why not the liver instead of the kidney?
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.
Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses by Alain H. Rook, Gary S. Wood, Elisa K. Yoo,
Central venous line–related thrombosis in children: association with central venous line location and insertion technique by Christoph Male, Peter Chait,
Alternate designs for conduct and analysis of phase I cancer trials
by Masako Moriuchi, Hiroyuki Moriuchi, and Anthony S. Fauci
Improved outcome in central nervous system aspergillosis, using voriconazole treatment by Stefan Schwartz, Markus Ruhnke, Patricia Ribaud, Lawrence Corey,
Next-generation leukemia immunotherapy
Reduced tumor load in peripheral blood after treatment with G-CSF and chemotherapy in children with tumors of the Ewing sarcoma family but not neuroblastoma.
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Detection of vascular endothelial growth factor in AIDS-related primary effusion lymphomas by Yoshiyasu Aoki, Giovanna Tosato, Yoshihiro Nambu, Aikichi.
How I treat elderly patients with myeloma
by Thomas Rasmussen, Linda Jensen, Lone Honoré, and Hans Erik Johnsen
Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.
by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C
Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation.
by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu
Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis by Lisa A. Michaels, Kwaku.
What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):
Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura by Evaren E. Page, Johanna A. Kremer.
by Wolfram Springer, Alexander von Ruecker, and Roswitha Dickerhoff
Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,
by Alexander Röth, Andreas Hüttmann, Russell P
Anti–factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome by Mihály Józsi, Stefanie Strobel, Hans-Martin.
Target recognition–induced NK-cell responses
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Stage C or not stage C…? by Claire Dearden Blood
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL by Ian W. Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Árpád Illés,
Human NK cells can control CMV infection in the absence of T cells
Blocking VWF platelet binding to treat TTP
Has MRD monitoring superseded other prognostic factors in adult ALL?
How I treat refractory CLL
Anergy: the CLL cell limbo
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232 by Michael J. Borowitz,
Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Prostaglandin E2 suppresses allergic sensitization and lung inflammation by targeting the E prostanoid 2 receptor on T cells  Zbigniew Zasłona, PhD, Katsuhide.
Prostaglandin E2 suppresses allergic sensitization and lung inflammation by targeting the E prostanoid 2 receptor on T cells  Zbigniew Zasłona, PhD, Katsuhide.
by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
by Nicholas J. Laping, Michael P. DeMartino, Joshua E
Activity of MAC-321 (i. v. and p. o
A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF ) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic.
Schematic model of the mechanism of Tak1 protection of HSPC survival.
Cytokine changes in LPS-induced TNFα and spontaneous IL-6 production in whole-blood cultures. Cytokine changes in LPS-induced TNFα and spontaneous IL-6.
(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.
Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but not OVA Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but.
EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,
Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device.
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
Immunologic and pharmacokinetic studies.
Impairment of liver function upon treatment with 4D5MOCB-ETA.
Full Uncapped Doses Of Chemotherapy In Non-Hodgkin's Lymphoma Patients With a High Body Surface Area Are Well Tolerated With No Increase In Toxicity, and.
Diagnoses in patients with TA-GVHD.
MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.
Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.
A, Changes in BRAFV600E cfDNA allele fraction from baseline after one dose of treatment for 12 patients with serial samples available, classified according.
A change in either volume of distribution or clearance has differing effects on the concentration-time profile. A change in either volume of distribution.
by Renato D. Lopes, Patrícia O. Guimarães, Bradley J. Kolls, Daniel M
Balancing bleeding in brain metastases
Cold agglutinin disease
Presentation transcript:

Downregulation of the Proinflammatory Cytokine Response to Endotoxin by Pretreatment With the Nontoxic Lipid A Analog SDZ MRL 953 in Cancer Patients by Alexander Kiani, Astrid Tschiersch, Elke Gaboriau, Florian Otto, Alexander Seiz, Hans-Peter Knopf, Peter Stütz, Lothar Färber, Ulrike Haus, Chris Galanos, Roland Mertelsmann, and Rupert Engelhardt Blood Volume 90(4):1673-1683 August 15, 1997 ©1997 by American Society of Hematology

Schematic illustration of the study protocol. Schematic illustration of the study protocol. Twenty patients, divided in five dose subgroups (18.0 to 39.6 μg/kg of BW), were treated with seven intravenous bolus injections of SDZ MRL 953 at the indicated time points. One of four patients was randomized to receive double-blind vehicle control instead of SDZ MRL 953. Three days after the last injection of SDZ MRL 953 or vehicle control, each patient was challenged with an intravenous bolus injection of endotoxin (2 ng/kg of BW). Patients were monitored closely for toxic effects of the drugs, and serial blood samples were drawn for hematologic changes and systemic cytokine release, as described in the Materials and Methods. Alexander Kiani et al. Blood 1997;90:1673-1683 ©1997 by American Society of Hematology

Alexander Kiani et al. Blood 1997;90:1673-1683 ©1997 by American Society of Hematology

Alexander Kiani et al. Blood 1997;90:1673-1683 ©1997 by American Society of Hematology

Alexander Kiani et al. Blood 1997;90:1673-1683 ©1997 by American Society of Hematology

Alexander Kiani et al. Blood 1997;90:1673-1683 ©1997 by American Society of Hematology

Alexander Kiani et al. Blood 1997;90:1673-1683 ©1997 by American Society of Hematology

Alexander Kiani et al. Blood 1997;90:1673-1683 ©1997 by American Society of Hematology

Alexander Kiani et al. Blood 1997;90:1673-1683 ©1997 by American Society of Hematology

Alexander Kiani et al. Blood 1997;90:1673-1683 ©1997 by American Society of Hematology

Alexander Kiani et al. Blood 1997;90:1673-1683 ©1997 by American Society of Hematology

Alexander Kiani et al. Blood 1997;90:1673-1683 ©1997 by American Society of Hematology

Alexander Kiani et al. Blood 1997;90:1673-1683 ©1997 by American Society of Hematology

Alexander Kiani et al. Blood 1997;90:1673-1683 ©1997 by American Society of Hematology